Literature DB >> 11594797

Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy.

B Chen1, T M Timiryasova, D S Gridley, M L Andres, R Dutta-Roy, I Fodor.   

Abstract

Single intratumoural treatment of nude mice with a vaccinia virus (VV)-expressing interleukin-1 (IL-2) or IL-12 induced significant tumour growth inhibition associated with clear signs of toxicity. At a low virus dose, only some treated animals showed signs of toxicity. We characterized and compared the activity of NK and B cells and major pro-inflammatory factors (IFN-gamma, TNF-alpha) in treated animals with and without toxicity. One week after treatment animals exhibiting signs of cytokine-related toxicity showed dramatic increases in several measured parameters. High leukocyte and lymphocyte counts in blood and marked increases in NK and CD25(+)cells in both blood and spleen were associated with IL-2-induced toxicity, while IL-12-induced toxicity was related to a great elevation of CD25(+)cells in blood and CD71(+)cells in the spleen. In contrast, immune activation in animals free of toxicity was observed on day 2 after the treatment, which drastically declined by day 7. Thus, immune responses induced by IL-2 and IL-12 therapy appear to play important roles in both tumour inhibition and the accompanying toxicity. Short-term effects induced by IL-2 and IL-12 could be critical for antitumour therapy that prolongs survival and protects from adverse side effects. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594797     DOI: 10.1006/cyto.2001.0906

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Tumor Therapy Applying Membrane-bound Form of Cytokines.

Authors:  Young Sang Kim
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

2.  Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits.

Authors:  Marianne M Stanford; John W Barrett; Philippe-Alexandre Gilbert; Richard Bankert; Grant McFadden
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

Review 3.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

4.  Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production.

Authors:  Luis G Bermúdez-Humarán; Philippe Langella; Naima G Cortes-Perez; Alexandra Gruss; Reyes S Tamez-Guerra; Sergio C Oliveira; Odila Saucedo-Cardenas; Roberto Montes de Oca-Luna; Yves Le Loir
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  Construction of IL-2 gene-modified human hepatocyte and its cultivation with microcarrier.

Authors:  Nan-Hong Tang; Yian-Ling Chen; Xiao-Qian Wang; Xiu-Jin Li; Feng-Zhi Yin; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

6.  Gene Therapy Applications to Cancer Treatment.

Authors:  Susy M. Scholl; Silke Michaelis; Ray McDermott
Journal:  J Biomed Biotechnol       Date:  2003

7.  Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.

Authors:  Anthony K Park; Yuman Fong; Sang-In Kim; Jason Yang; John P Murad; Jianming Lu; Brook Jeang; Wen-Chung Chang; Nanhai G Chen; Sandra H Thomas; Stephen J Forman; Saul J Priceman
Journal:  Sci Transl Med       Date:  2020-09-02       Impact factor: 19.319

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.